Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 11 studies | 25% ± 9% | |
natural killer cell | 11 studies | 24% ± 10% | |
CD8-positive, alpha-beta T cell | 9 studies | 25% ± 8% | |
CD16-positive, CD56-dim natural killer cell, human | 7 studies | 20% ± 3% | |
CD16-negative, CD56-bright natural killer cell, human | 6 studies | 18% ± 1% | |
endothelial cell | 5 studies | 24% ± 5% | |
pro-B cell | 5 studies | 38% ± 4% | |
fibroblast | 5 studies | 24% ± 8% | |
CD4-positive, alpha-beta T cell | 5 studies | 25% ± 7% | |
B cell | 4 studies | 22% ± 7% | |
conventional dendritic cell | 4 studies | 33% ± 16% | |
non-classical monocyte | 4 studies | 28% ± 7% | |
neuron | 4 studies | 45% ± 22% | |
gamma-delta T cell | 4 studies | 25% ± 11% | |
regulatory T cell | 4 studies | 18% ± 1% | |
classical monocyte | 3 studies | 27% ± 7% | |
mature NK T cell | 3 studies | 18% ± 1% | |
connective tissue cell | 3 studies | 23% ± 5% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 29% ± 8% | |
dendritic cell | 3 studies | 35% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 1020.51 | 180 / 180 | 100% | 42.67 | 430 / 430 |
skin | 100% | 1307.95 | 1809 / 1809 | 100% | 60.26 | 472 / 472 |
brain | 100% | 1120.76 | 2641 / 2642 | 100% | 57.52 | 705 / 705 |
uterus | 100% | 1116.69 | 170 / 170 | 100% | 51.57 | 457 / 459 |
prostate | 100% | 1138.73 | 245 / 245 | 99% | 34.73 | 498 / 502 |
thymus | 100% | 808.12 | 652 / 653 | 99% | 36.07 | 601 / 605 |
breast | 100% | 1269.48 | 459 / 459 | 99% | 33.44 | 1102 / 1118 |
lung | 100% | 1465.37 | 577 / 578 | 98% | 34.71 | 1134 / 1155 |
liver | 100% | 1268.77 | 226 / 226 | 98% | 28.00 | 397 / 406 |
intestine | 99% | 960.86 | 961 / 966 | 98% | 25.61 | 516 / 527 |
bladder | 100% | 1131.05 | 21 / 21 | 97% | 39.61 | 490 / 504 |
pancreas | 100% | 1056.80 | 328 / 328 | 97% | 23.79 | 173 / 178 |
stomach | 100% | 1063.88 | 359 / 359 | 97% | 24.64 | 277 / 286 |
esophagus | 100% | 950.97 | 1442 / 1445 | 97% | 28.63 | 177 / 183 |
kidney | 100% | 1282.12 | 89 / 89 | 93% | 17.00 | 842 / 901 |
adrenal gland | 100% | 903.52 | 258 / 258 | 88% | 17.23 | 202 / 230 |
adipose | 100% | 1203.50 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 68.35 | 29 / 29 |
muscle | 100% | 1341.93 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1217.07 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 43.85 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.11 | 1 / 1 |
blood vessel | 100% | 907.54 | 1332 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1669.07 | 924 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 28.89 | 79 / 80 |
heart | 98% | 760.31 | 840 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042177 | Biological process | negative regulation of protein catabolic process |
GO_0001558 | Biological process | regulation of cell growth |
GO_0042276 | Biological process | error-prone translesion synthesis |
GO_0006302 | Biological process | double-strand break repair |
GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
GO_0051301 | Biological process | cell division |
GO_0010944 | Biological process | negative regulation of transcription by competitive promoter binding |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_1901203 | Biological process | positive regulation of extracellular matrix assembly |
GO_2000678 | Biological process | negative regulation of transcription regulatory region DNA binding |
GO_0010719 | Biological process | negative regulation of epithelial to mesenchymal transition |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0007015 | Biological process | actin filament organization |
GO_1904667 | Biological process | negative regulation of ubiquitin protein ligase activity |
GO_0043247 | Biological process | telomere maintenance in response to DNA damage |
GO_0042772 | Biological process | DNA damage response, signal transduction resulting in transcription |
GO_0010718 | Biological process | positive regulation of epithelial to mesenchymal transition |
GO_0007094 | Biological process | mitotic spindle assembly checkpoint signaling |
GO_2000048 | Biological process | negative regulation of cell-cell adhesion mediated by cadherin |
GO_0002208 | Biological process | somatic diversification of immunoglobulins involved in immune response |
GO_2000042 | Biological process | negative regulation of double-strand break repair via homologous recombination |
GO_2001034 | Biological process | positive regulation of double-strand break repair via nonhomologous end joining |
GO_0045830 | Biological process | positive regulation of isotype switching |
GO_0005680 | Cellular component | anaphase-promoting complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016035 | Cellular component | zeta DNA polymerase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005694 | Cellular component | chromosome |
GO_0000785 | Cellular component | chromatin |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005819 | Cellular component | spindle |
GO_0005634 | Cellular component | nucleus |
GO_0008432 | Molecular function | JUN kinase binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAD2L2 |
Protein name | Mitotic spindle assembly checkpoint protein MAD2B (Mitotic arrest deficient 2-like protein 2) Mitotic arrest deficient 2 like 2 Mitotic spindle assembly checkpoint protein MAD2B (Mitotic arrest deficient 2-like protein 2) (MAD2-like protein 2) (REV7 homolog) (hREV7) |
Synonyms | REV7 MAD2B |
Description | FUNCTION: Adapter protein able to interact with different proteins and involved in different biological processes . Mediates the interaction between the error-prone DNA polymerase zeta catalytic subunit REV3L and the inserter polymerase REV1, thereby mediating the second polymerase switching in translesion DNA synthesis . Translesion DNA synthesis releases the replication blockade of replicative polymerases, stalled in presence of DNA lesions . Component of the shieldin complex, which plays an important role in repair of DNA double-stranded breaks (DSBs) . During G1 and S phase of the cell cycle, the complex functions downstream of TP53BP1 to promote non-homologous end joining (NHEJ) and suppress DNA end resection . Mediates various NHEJ-dependent processes including immunoglobulin class-switch recombination, and fusion of unprotected telomeres . May also regulate another aspect of cellular response to DNA damage through regulation of the JNK-mediated phosphorylation and activation of the transcriptional activator ELK1 . Inhibits the FZR1- and probably CDC20-mediated activation of the anaphase promoting complex APC thereby regulating progression through the cell cycle . Regulates TCF7L2-mediated gene transcription and may play a role in epithelial-mesenchymal transdifferentiation . . |
Accessions | ENST00000456915.2 ENST00000376669.9 ENST00000376692.9 ENST00000235310.7 ENST00000697272.1 B1AK45 A0A8V8TL87 B1AK44 ENST00000456915.1 ENST00000445656.5 A0A8V8TMF5 ENST00000376672.5 Q9UI95 ENST00000376667.7 B1AK43 ENST00000697273.1 A0A8V8TKV6 ENST00000697274.1 |